We limit data available in the Overview Report for users who do not have Powerpack
Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Target Price Range
Recommendation Rating
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 39.12 | 4.32 | — | — | — |
Low Price
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 173.04 | 100.56 | — | — | — |
High Price
|
| — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 30 | 29 | — | — | — |
Employees
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.02 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.45 | 0.06 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Revenue
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 100.00% | 100.00% | — | — | — |
Gross Margin
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.41) | (14.45) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
EBT
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2,980.00%) | (24,091.67%) | ‡‡‡ | ‡‡‡ | — |
EBT Margin
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.57) | (14.45) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Net Income
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.26 | 0.29 | — | — | — |
Depreciation
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.20 | 0.18 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Revenue/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (66.19) | (43.64) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Earnings/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (55.63) | (30.39) | — | — | — |
Cash Flow/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.75) | (0.14) | ‡‡‡ | ‡‡‡ | — |
Capex/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (56.38) | (30.53) | — | — | — |
Free CF/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 21.46 | (7.49) | — | — | — |
Book Value/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.21 | 0.33 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Shares
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
PE Ratio
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 18.70 | 5.54 | ‡‡‡ | ‡‡‡ | — |
PS Ratio
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.91 | 0.00 | ‡‡‡ | ‡‡‡ | — |
PB Ratio
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 14.92 | 11.80 | ‡‡‡ | ‡‡‡ | — |
EV/Sales
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.58) | (0.42) | — | — | — |
EV/FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (11.40) | (10.07) | ‡‡‡ | ‡‡‡ | — |
Op' Cash Flow
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.15) | (0.05) | ‡‡‡‡‡ | — | — |
Capex
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (11.56) | (10.11) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.41 | (3.46) | — | — | — |
Working Cap'
|
| — | — | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.65 | — | — | — | — |
Total Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.70) | (1.07) | — | — | — |
Net Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.40 | (2.48) | — | — | — |
Sh' Equity
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (95.20%) | (241.08%) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
ROA
|
| — | — | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (311.02%) | 0.00% | — | — | — |
ROIC
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (132.83%) | (1,508.09%) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
ROE
|
Analyst Commentary (Summary)
Metabolix, Inc. (YTENQ) Latest News
14 Aug
Yield10 Bioscience reported financial results for Q2 2024, including a net loss of $3.2 million. They are finalizing an asset purchase agreement with Nufarm and received an initial $3 million payment. The financial results and progress on the asset purchase agreement may moderately influence Yield10's future financial performance and strategic direction.
17 Jul
Yield10 Bioscience grants Nufarm a commercial license to Omega-3 assets for producing oil in Camelina and signs a Memorandum of Understanding for sale of assets. The agreement with Nufarm and potential sale of assets could significantly impact Metabolix, Inc.'s future strategic direction and market positioning.
Yield10 Bioscience grants Nufarm a commercial license for Omega-3 assets in Camelina and negotiates sale of assets to Nufarm. The agreement with Nufarm for Omega-3 assets and potential sale of assets could significantly impact Metabolix, Inc.'s future strategic direction and market positioning.
17 Jun
Yield10 Bioscience granted exclusive global license to produce omega-3 products in Camelina by Rothamsted Research. The exclusive license for producing omega-3 products in Camelina has the potential to significantly impact Yield10 Bioscience's future market performance and strategic positioning.
23 May
EPA approved amendment to INTERLINE herbicide label to include Camelina for weed control during field production. Approval of Camelina in INTERLINE herbicide label is a significant move that can impact Yield10's future market performance and strategic positioning.
15 May
Yield10 Bioscience reports Q1 2024 financial results, earns $1 million milestone payment from Vision Bioenergy Oilseeds, focuses on commercializing Camelina products for aquafeed and nutritional markets. The strategic decisions and milestones achieved by Yield10 Bioscience in Q1 2024 are expected to significantly impact its future commercialization efforts and market positioning.
Yield10 Bioscience announced delisting from Nasdaq due to failure to meet stockholders' equity requirement. Delisting from Nasdaq may moderately affect financial performance and competitive positioning.
5 Apr
Yield10 Bioscience, Inc. (NASDAQ:YTEN) Q4 2023 Earnings Call Transcript reports missed earnings expectations. The missed earnings and strategic focus on biofuels could moderately influence the company's future performance.
2 Apr
Yield10 Bioscience Inc reported Q4 2023 financial results, focusing on commercializing omega-3 products and licensing Camelina technologies for biofuels. Achieved regulatory approvals for herbicide-tolerant Camelina. Received $3 million payment from Vision Bio for licensing agreement. Significant impact likely on future performance due to progress in commercializing omega-3 products and licensing agreements for biofuels.
1 Apr
Yield10 Bioscience reports financial results for Q4 and full year 2023, focusing on commercialization of Camelina products for biofuels and omega-3 oils. The article highlights significant milestones achieved in commercialization efforts and regulatory approvals, indicating a potential significant impact on future revenue and market positioning.
28 Mar
Yield10 Bioscience to announce fourth quarter and full year 2023 financial results and host a conference call on Monday, April 1, 2024. The financial results and corporate update may moderately influence key areas such as financial performance and market sentiment.
26 Mar
Yield10 Bioscience's E3902 Camelina cleared for planting in Canada by CFIA. Regulatory approval in multiple countries for genome-edited Camelina expected to significantly impact future market performance.
21 Mar
USDA-APHIS determines that Yield10 Bioscience's Omega-3 Camelina varieties may be planted and bred in the United States. The approval for commercial scale production of omega-3 fatty acids in Camelina could significantly impact Metabolix, Inc.'s future market performance and strategic positioning.
29 Feb
Yield10 Bioscience reports success in field tests for herbicide tolerance in winter Camelina varieties. The development of herbicide tolerant Camelina varieties could significantly impact the company's future market performance and competitive positioning.
14 Feb
Yield10 Bioscience grants global license to VISION Bioenergy Oilseeds for herbicide tolerant Camelina cultivated for biofuel feedstock. The global license agreement for herbicide tolerant Camelina is a significant move that can impact Yield10's future market performance and strategic positioning.
7 Feb
Yield10 Bioscience prioritizes activities to advance Omega-3 Camelina program in 2024, completes contra season production in Chile, and provides update on Nasdaq status. The completion of contra season production and progress towards commercializing Omega-3 Camelina could have a significant impact on Metabolix, Inc.'s future and market performance.
8 Jan
Yield10 Bioscience files for regulatory status review with USDA-APHIS for Camelina designed to produce EPA and DHA components of Omega-3 oil. Development of land-based production of omega-3 oils with potential to address global demand and serve as a sustainable alternative to fish oil.
16 Nov
Yield10 Bioscience, Inc. (NASDAQ:YTEN) Q3 2023 Earnings Call Transcript highlights progress in Camelina platform crop for biofuels and omega-3 oils, regulatory approvals for herbicide tolerant Camelina, financial results, and upcoming milestones. Significant impact expected on Metabolix, Inc. (YTEN) future with regulatory approvals, progress in biofuels and omega-3 oils, and upcoming milestones.
15 Nov
USDA-APHIS allows Yield10 Bioscience to grow and breed stacked herbicide tolerant Camelina in the US. The approval of stacked herbicide tolerant Camelina varieties is a significant milestone that can enable large-acreage adoption of the crop in North America.
USDA-APHIS approves glufosinate tolerant Camelina for planting in the US, Yield10 aims for commercial launch by 2025. Approval of glufosinate tolerant Camelina and potential commercial launch by 2025 could significantly impact Yield10's future market performance.
14 Nov
Yield10 Bioscience reports financial results for Q3 2023, advances herbicide tolerant Camelina varieties, and finalizes exclusive license for omega-3 technology in Camelina. The article describes significant developments in Yield10's core operations and strategic partnerships that could have a major impact on its future performance.
8 Nov
Yield10 Bioscience to announce third quarter 2023 financial results and host a conference call on Tuesday, November 14, 2023. The financial results and corporate update may moderately influence market sentiment and financial performance.
31 Oct
Yield10 Bioscience and BioMar Group partner to commercialize Omega-3 Camelina crop for aquafeed industry. Partnership with BioMar to commercialize Omega-3 Camelina technology can significantly impact Metabolix, Inc.'s future market performance.
18 Oct
Yield10 Bioscience finalizes exclusive global license for omega-3 Camelina technology from Rothamsted Research. The exclusive license for advanced omega-3 production technology has the potential to significantly impact Metabolix, Inc.'s future market performance and strategic positioning.
11 Oct
Yield10 Bioscience advances in developing herbicide tolerant Camelina for biofuel market. Development of herbicide tolerant Camelina varieties with potential to impact biofuel market significantly.
3 Oct
Yield10 Bioscience completes harvest of Camelina grain grown under contract, generating revenue from biofuel production. The completion of the harvest and revenue generation from biofuel production signifies a significant strategic move that could alter the company's trajectory and investor sentiment.
Yield10 Bioscience (YTENQ), formerly Metabolix, has cratered from biotech pioneer to OTC penny stock oblivion, its price effectively zero amid relentless cash burn and dilution that ballooned shares 11,000% since 2016. Once chasing biopolymers and biofuels, it pivoted to CRISPR-like gene-editing for super-yield camelina and canola, but revenue imploded 95% to $60,000 by 2023, with productivity metrics like revenue per employee down 96%. Deep losses, negative equity, and zero insider buying scream distress, yet analysts unanimously flash 100%+ upside targets—pure speculative lottery tickets betting on trial breakthroughs against bankruptcy whispers.
Gross margins stay perfect at 100%, hinting at tech promise if sales ever scale, but forecasts of $1.2 million revenue in 2024-2025 feel like wishful thinking amid sector giants like Bayer dominating. Free cash flow bleeds persist, ROE tanks to -95%, and history of delistings, trial flops (mere 20-50% yield bumps vs. needed 100%), and GMO hurdles paint a grim execution failure.
This agritech gamble embodies promise-peril extremes: C3008 camelina could royalty-disrupt $50B oilseed markets, sparking M&A frenzy, or dissolve into zero recovery. Contrarians beware the hype—dilution traps and frothy valuations have crushed far better stories, but binary catalysts might deliver moonshot rewards for the bold.